Please login to the form below

Not currently logged in
Email:
Password:

EMA’s Pharmacovigilance Risk Assessment Committee gains new members

Filip Babylon to represent HCP organisations and Albert van der Zeijden to represent patient organisations

EMA PRAC Albert van der ZeijdenThe European Medicines Agency's (EMA) newest committee - the Pharmacovigilance Risk Assessment Committee (PRAC) - has added two new members.

Filip Babylon, president of the Belgian Pharmaceutical Association (APB), will represent healthcare professionals' organisations and Albert van der Zeijden (pictured right), chairman of the International Alliance of Patients Organisations (IAPO), will represent patient organisations.

The PRAC was formed as part of European pharmacovigilance legislation implemented last year, and had its first meeting in July 2012.

Its objective is to assess and monitor safety issues for human medicines, giving recommendations for consideration by the Committee for Medicinal Products for Human Use (CHMP).

Its current chair is Dr June Raine of the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Its new members Babylon and van der Zeijden will participate in the PRAC from April 2013.

The EMA said: “Their role is to bring the views, concerns and experiences of patients and doctors to the PRAC's scientific considerations thus enriching its decision-making.”

Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.

12th March 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics